Rexulti, also known as brexpiprazole, was first approved by the U.S. Food and Drug Administration (FDA) on July 10, 2015 [1]. It is manufactured by Otsuka Pharmaceutical Co., Ltd. and Lundbeck [2].
What is Rexulti used for?
Rexulti is prescribed to treat adults with major depressive disorder (MDD) as an add-on treatment and for the treatment of schizophrenia [2].
How does Rexulti work?
Rexulti is classified as a serotonin-dopamine activity modulator [3]. It works by affecting the levels of certain neurotransmitters in the brain, specifically dopamine and serotonin, which are thought to play a role in mood and behavior [3].
What are the potential side effects of Rexulti?
Common side effects associated with Rexulti can include akathisia (a feeling of inner restlessness), weight gain, headache, and somnolence (drowsiness) [2].
When does Rexulti's patent expire?
The patent landscape for Rexulti involves multiple patents covering its composition, use, and manufacturing. DrugPatentWatch.com tracks these patents, which can influence market exclusivity [4]. Exclusivity periods can be extended by regulatory actions or further patent filings.
Who are Rexulti's competitors?
In the treatment of schizophrenia and major depressive disorder, Rexulti competes with other antipsychotic and antidepressant medications. Competitors may include drugs like Abilify (aripiprazole), Vraylar (cariprazine), and others that modulate dopamine and serotonin pathways [5].